University of Oxford

Doctor prepares vaccine
#Barinthus Biotherapeutics #CEPI #Immunology / Virology & Vaccines #Partnership #University of Oxford

Partnership to fast-track MERS vaccine

UK-based Barinthus Biotherapeutics, the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford are working together to fast-track the development of a vaccine candidate for the prevention of Middle East Respiratory Syndrome (MERS). The partners plan to take a MERS vaccine from early development through Phase II clinical… Read More

#Business & Investment #News

Doctor prepares vaccine
#Funding #Immunology #Immunology / Virology & Vaccines #Pandemic prevention #University of Oxford

University of Oxford receives £7.8 million to fight pandemic threats

The Oxford Vaccine Group (OVG), which led the development of the Oxford vaccine for Covid-19, has been awarded a total of £7.8 ($9.8) million by UK Aid for research into the prevention of five diseases with epidemic or pandemic potential. The awards will fund research into… Read More

#News

Bacteria
#Antibiotics #Antimicrobial resistance (AMR) #Funding #Glox Therapeutics #University of Glasgow #University of Oxford

University spin-out secures £4.3M to develop precision antibiotics

Glox Therapeutics has raised £4.3M ($5.2M) in seed funding to develop targeted therapeutics against antibiotic-resistant Gram-negative bacteria. The company will use the funding to establish laboratories in Oxford and Glasgow and expand its team to accelerate its bacteriocin development programme. Glox Therapeutics is developing precision antibiotics using engineered protein bacteriocins. Read More

#Business & Investment #News #Trending News

#Career #Interview #Meet the Researcher #Nanomedicine / nanotechnology #University of Oxford

Meet the researcher: Molly Stevens, Oxford University and Imperial

Listen to this article on the DDW Podcast: Megan Thomas talks to Molly Stevens, John Black Professor at Oxford University and Research Director for Biomedical Materials at Imperial College London. MT: Where do you work, and can you tell us what you’re working on at the moment? MS: I am going… Read More

#Exclusive Content

Doctor administering a vaccine to patient
#Covid-19 vaccine #Flu vaccine #Immunology / Virology & Vaccines #Influenza #University of Oxford

Oxford study to allow tailoring of Covid-19 and flu vaccines

The Oxford Vaccine Group at the University of Oxford, UK, has launched the LEGACY03 study into human immunity, aimed to improve the design of seasonal vaccines and allow targeting by age group. This study, funded by the Medical Research Council, will test the responses of cells… Read More

#News

Antibodies attack Covid-19
#Covid-19 #Harvard Medical School #Immunology / Virology & Vaccines #Pandemic prevention #Pandemic response #University of Oxford

AI tool predicts new viral variants and could improve vaccines

The UK’s University of Oxford is taking the lead on two collaborative international projects to improve the response to new Covid-19 variants and contribute to future pandemic preparedness. Researchers at Harvard Medical School (HMS) in the US and the University of Oxford have developed a new… Read More

#News #Trending News

Mosquito against yellow background
#Immunology / Virology & Vaccines #Malaria #Novavax #Serum Institute of India #University of Oxford #WHO

WHO recommends new cost-effective malaria vaccine

The R21/Matrix-M malaria vaccine has been recommended for use by the World Health Organization’s Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG). Developed by The University of Oxford and the Serum Institute of India, leveraging Novavax’s adjuvant technology, R21/Matrix-M malaria vaccine demonstrates high efficacy with… Read More

#News #Regulatory #Trending News

Vaccine vial and syringe
#Clinical trial #Immunology / Virology & Vaccines #Nipah Virus #University of Oxford

UK scientists prepare for Nipah virus clinical trial

The University of Oxford has revealed that researchers are currently in the advanced stages of preparing for a clinical trial of a Nipah vaccine using the ChAdOx1 vector. The scientists are also working with partners to develop antivirals and monoclonals to treat those infected, according to… Read More

#News

Endometriosis
#Endometriosis #Genetics / genomics #Personalised medicine #PrecisionLife #University of Oxford #Women's health

Endometriosis partners to discover personalised treatments

PrecisionLife and the University of Oxford have signed a data access agreement to license the Oxford Endometriosis Gene (OXEGENE) dataset to develop new personalised treatments for endometriosis patients. Endometriosis affects 10% of women globally, but on average it takes over seven years for patients to receive… Read More

#News

Covid-19
#Axcella Therapeutics #Covid-19 #Long Covid #Mitochondria #Phase II trial #University of Oxford

Encouraging trial results for long Covid fatigue treatment

Researchers from the University of Oxford have reported findings from a Phase II clinical trial investigating the efficacy of an investigational treatment against long Covid fatigue. The study found that participants given the treatment, AXA1125, developed by US pharmaceutical company Axcella Therapeutics, felt less fatigued than… Read More

#Editor's Choice #News

Malaria vaccine
#Africa #Immunology / Virology & Vaccines #Malaria #Regulatory #Serum Institute of India #University of Oxford #Vaccines

Ghana vaccine approval a ‘critical step’ in combatting malaria

The R21/Matrix-M malaria vaccine has received regulatory clearance for use in Ghana by the country’s Food and Drugs Authority, making it the first country to approve the vaccine. R21/Matrix-M was developed by the University of Oxford and manufactured and scaled up by the Serum Institute of India (SIIPL), leveraging Novavax’s… Read More

#News #Regulatory #Trending News

Doctor looks at x-ray of the lungs
#Immunity #TB vaccine #Tuberculosis #University of Oxford

Study insights may aid TB vaccine development

New research has furthered our understanding of the immune-related factors that drive infection and disease, which will be necessary for an effective tuberculosis (TB) vaccine to be developed. Researchers from the University of Oxford investigated whether previously identified correlates of protection associated with risk of full-blown TB disease could also… Read More

#News

#British Heart Foundation (BHF) #CRISPR #Gene editing #Heart disease #University of Oxford

International researchers win £30m for work in treating heart conditions  

An international team of researchers has won £30 million for its work in developing a potential cure for inherited heart muscle conditions in young people.  CureHeart was selected as the winner of the British Heart Foundation’s (BHF) Big Beat Challenge, which grants a £30 million non-commercial grant… Read More

#News